{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:43:52Z","timestamp":1776185032770,"version":"3.50.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Recognize the classification, clinical presentation, and diagnosis of embryonal CNS tumors. Explain the important molecular genetic alterations identified in embryonal CNS tumors. Describe the current management and novel treatment strategies for embryonal CNS tumors.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Embryonal central nervous system (CNS) tumors are the most common group of malignant brain tumors in children. The diagnosis and classification of tumors belonging to this family have been controversial; however, utilization of molecular genetics is helping to refine traditional histopathologic and clinical classification schemes. Currently, this group of tumors includes medulloblastomas, supratentorial primitive neuroectodermal tumors, atypical teratoid\/rhabdoid tumors, ependymoblastomas, and medulloepitheliomas. While the survival of older children with nonmetastatic medulloblastomas has improved considerably within the past two decades, the outcomes for infants and for those with metastatic medulloblastomas or other high-risk embryonal CNS tumors remain poor. It is anticipated that the emerging field of molecular biology will greatly aid in the future stratification and therapy for pediatric patients with malignant embryonal tumors. In this review, recent advances in the diagnosis, molecular genetics, and treatment of the most common pediatric embryonal CNS tumors are discussed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.8-2-174","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"174-186","source":"Crossref","is-referenced-by-count":68,"title":["Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors"],"prefix":"10.1093","volume":"8","author":[{"given":"Tobey J.","family":"MacDonald","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Children's Hospital National Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Rood","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Children's Hospital National Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Santi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Children's Hospital National Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Vezina","sequence":"additional","affiliation":[{"name":"Department of Radiology, Children's Hospital National Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Bingaman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Children's Hospital National Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip H.","family":"Cogen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Children's Hospital National Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children's Hospital National Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2003,4,1]]},"reference":[{"key":"2021122209332137300_R1","first-page":"51","volume-title":"Cancer incidence and survival among children and adolescents: United States SEER Program 1975\u20131995. NIH Pub No 99-4649","author":"Gurney","year":"1999"},{"key":"2021122209332137300_R2","first-page":"123","volume-title":"World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System","author":"Becker","year":"2000"},{"key":"2021122209332137300_R3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/415436a","article-title":"Prediction of central nervous system embryonal tumour outcome based on gene expression","volume":"415","author":"Pomeroy","year":"2002","journal-title":"Nature"},{"key":"2021122209332137300_R4","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.1999.17.3.832","article-title":"Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study","volume":"17","author":"Zeltzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122209332137300_R5","first-page":"164","article-title":"A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression","volume":"3","author":"Coffin","year":"1990","journal-title":"Mod Pathol"},{"key":"2021122209332137300_R6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/1097-0142(19810215)47:4<772::AID-CNCR2820470423>3.0.CO;2-E","article-title":"Cerebellar \u201cneuroblastoma\u201d: nosology as it relates to medulloblastoma","volume":"47","author":"Pearl","year":"1981","journal-title":"Cancer"},{"key":"2021122209332137300_R7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/1097-0142(197310)32:4<890::AID-CNCR2820320421>3.0.CO;2-O","article-title":"Primitive neuroectodermal tumors of the brain in children","volume":"32","author":"Hart","year":"1973","journal-title":"Cancer"},{"key":"2021122209332137300_R8","first-page":"498","article-title":"Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins","volume":"62","author":"Gould","year":"1990","journal-title":"Lab Invest"},{"key":"2021122209332137300_R9","doi-asserted-by":"crossref","first-page":"12867","DOI":"10.1073\/pnas.91.26.12867","article-title":"Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma","volume":"91","author":"Segal","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209332137300_R10","first-page":"711","article-title":"Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas","volume":"59","author":"Kim","year":"1999","journal-title":"Cancer Res"},{"key":"2021122209332137300_R11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2000.18.5.1027","article-title":"TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors","volume":"18","author":"Grotzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209332137300_R12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/bjc.1995.96","article-title":"Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma","volume":"71","author":"Gilbertson","year":"1995","journal-title":"Br J Cancer"},{"key":"2021122209332137300_R13","first-page":"2425","article-title":"MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor\/medulloblastoma","volume":"7","author":"Grotzer","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122209332137300_R14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5858\/2002-126-0540-MAMOAI","article-title":"MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group","volume":"126","author":"Aldosari","year":"2002","journal-title":"Arch Pathol Lab Med"},{"key":"2021122209332137300_R15","first-page":"842","article-title":"Sporadic medulloblastomas contain PTCH mutations","volume":"57","author":"Raffel","year":"1997","journal-title":"Cancer Res"},{"key":"2021122209332137300_R16","first-page":"513","article-title":"Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched","volume":"61","author":"Wetmore","year":"2001","journal-title":"Cancer Res"},{"key":"2021122209332137300_R17","first-page":"473","article-title":"Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system","volume":"3","author":"Biegel","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2021122209332137300_R18","first-page":"3794","article-title":"Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma","volume":"62","author":"Rood","year":"2002","journal-title":"Cancer Res"},{"key":"2021122209332137300_R19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1215\/15228517-1-2-139","article-title":"Cytogenetics and molecular genetics of childhood brain tumors","volume":"1","author":"Biegel","year":"1999","journal-title":"Neuro-oncol"},{"key":"2021122209332137300_R20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3171\/jns.2000.93.3.0437","article-title":"Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping","volume":"93","author":"Bayani","year":"2000","journal-title":"J Neurosurg"},{"key":"2021122209332137300_R21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-4608(96)00319-6","article-title":"Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system","volume":"97","author":"Burnett","year":"1997","journal-title":"Cancer Genet Cytogenet"},{"key":"2021122209332137300_R22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1052>3.0.CO;2-S","article-title":"Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs","volume":"30","author":"Fruhwald","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"2021122209332137300_R23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/ng731","article-title":"Expression profiling of medulloblastoma: PDGFRA and the RAS\/MAPK pathway as therapeutic targets for metastatic disease","volume":"29","author":"MacDonald","year":"2001","journal-title":"Nat Genet"},{"key":"2021122209332137300_R24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1215\/15228517-1-3-232","article-title":"Medulloblastoma: clinical and biologic aspects","volume":"1","author":"Packer","year":"1999","journal-title":"Neuro-oncol"},{"key":"2021122209332137300_R25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s003810100446","article-title":"Uncommon presentation of medulloblastoma","volume":"17","author":"Kumar","year":"2001","journal-title":"Childs Nerv Syst"},{"key":"2021122209332137300_R26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s002340100603","article-title":"Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors","volume":"43","author":"Erdem","year":"2001","journal-title":"Neuroradiology"},{"key":"2021122209332137300_R27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004728-198909000-00005","article-title":"MR findings on primitive neuroectodermal tumors","volume":"13","author":"Figeroa","year":"1989","journal-title":"J Comput Assist Tomogr"},{"key":"2021122209332137300_R28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0360-3016(88)90385-9","article-title":"Medulloblastoma: staging and treatment outcome","volume":"14","author":"Deutsch","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209332137300_R29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0360-3016(98)00262-4","article-title":"Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation","volume":"42","author":"Saran","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209332137300_R30","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199306173282401","article-title":"Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors","volume":"328","author":"Duffner","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122209332137300_R31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00006123-199602000-00007","article-title":"Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group","volume":"38","author":"Albright","year":"1996","journal-title":"Neurosurgery"},{"key":"2021122209332137300_R32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0360-3016(99)00369-7","article-title":"Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT \u201891","volume":"46","author":"Kortmann","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209332137300_R33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000120797","article-title":"Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting","volume":"2","author":"Lee","year":"1994","journal-title":"Pediatr Neurosurg"},{"key":"2021122209332137300_R34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1227\/00006123-199511000-00006","article-title":"Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology","volume":"37","author":"Pollack","year":"1995","journal-title":"Neurosurgery"},{"key":"2021122209332137300_R35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000120761","article-title":"The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood","volume":"20","author":"Cochrane","year":"1994","journal-title":"Pediatr Neurosurg"},{"key":"2021122209332137300_R36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/jnnp.67.6.755","article-title":"Tumour type and size are high risk factors for the syndrome of \u201ccerebellar\u201d mutism and subsequent dysarthria","volume":"67","author":"Catsman-Berrevoets","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122209332137300_R37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0360-3016(92)91025-I","article-title":"M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided","volume":"24","author":"Bouffet","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209332137300_R38","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.1999.17.7.2127","article-title":"Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study","volume":"17","author":"Packer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122209332137300_R39","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1200\/JCO.2001.19.15.3470","article-title":"Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study","volume":"19","author":"Ris","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209332137300_R40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.1998.16.1.222","article-title":"High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group","volume":"16","author":"Dunkel","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209332137300_R41","first-page":"448a","article-title":"Atypical teratoid tumor of infancy: definition of an entity","volume":"22","author":"Lefkowitz","year":"1987","journal-title":"Ann Neurol"},{"key":"2021122209332137300_R42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3171\/jns.1996.85.1.0056","article-title":"Central nervous system atypical teratoid\/rhabdoid tumors of infancy and childhood: definition of an entity","volume":"85","author":"Rorke","year":"1996","journal-title":"J Neurosurg"},{"key":"2021122209332137300_R43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3171\/jns.1990.73.5.0710","article-title":"Monosomy 22 in rhabdoid or atypical tumors of the brain","volume":"73","author":"Biegel","year":"1990","journal-title":"J Neurosurg"},{"key":"2021122209332137300_R44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/00000478-199809000-00007","article-title":"Atypical teratoid\/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study","volume":"22","author":"Burger","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"2021122209332137300_R45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00043426-199502000-00013","article-title":"Successful treatment of disseminated central nervous system malignant rhabdoid tumor","volume":"17","author":"Olson","year":"1995","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"2021122209332137300_R46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S0317167100038191","article-title":"Malignant rhabdoid tumor of brain: an aggressive clinical entity","volume":"23","author":"Fisher","year":"1996","journal-title":"Can J Neurol Sci"},{"key":"2021122209332137300_R47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1006125120866","article-title":"Central nervous system atypical teratoid tumor\/rhabdoid tumor: response to intensive therapy and review of the literature","volume":"40","author":"Hilden","year":"1998","journal-title":"J Neurooncol"},{"key":"2021122209332137300_R48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2176\/nmc.39.510","article-title":"Clinicopathological characteristics of atypical teratoid\/rhabdoid tumor","volume":"39","author":"Oka","year":"1999","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2021122209332137300_R49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s004010051149","article-title":"Atypical teratoid\/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor\/medulloblastoma","volume":"99","author":"Ho","year":"2000","journal-title":"Acta Neuropathol (Berl)"},{"key":"2021122209332137300_R50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/01913129709021935","article-title":"Central nervous system atypical teratoid\/rhabdoid tumors of infancy and childhood","volume":"21","author":"Bhattacharjee","year":"1997","journal-title":"Ultrastruct Pathol"},{"key":"2021122209332137300_R51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/28212","article-title":"Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer","volume":"394","author":"Versteege","year":"1998","journal-title":"Nature"},{"key":"2021122209332137300_R52","first-page":"74","article-title":"Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors","volume":"59","author":"Biegel","year":"1999","journal-title":"Cancer Res"},{"key":"2021122209332137300_R53","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1126\/science.7801128","article-title":"Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5","volume":"266","author":"Kalpana","year":"1994","journal-title":"Science"},{"key":"2021122209332137300_R54","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/hmg\/8.13.2359","article-title":"Spectrum of hSNF5\/INI1 somatic mutations in human cancer and genotype-phenotype correlations","volume":"8","author":"Sevenet","year":"1999","journal-title":"Hum Mol Genet"},{"key":"2021122209332137300_R55","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1086\/302639","article-title":"Constitutional mutations of the hSNF5\/INI1 gene predispose to a variety of cancers","volume":"65","author":"Sevenet","year":"1999","journal-title":"Am J Hum Genet"},{"key":"2021122209332137300_R56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00043426-200206000-00004","article-title":"Atypical teratoid\/rhabdoid tumor of the central nervous system: report on workshop","volume":"24","author":"Packer","year":"2002","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"2021122209332137300_R57","first-page":"227","article-title":"High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study","volume":"9","author":"Kalifa","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"2021122209332137300_R58","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1998.16.1.210","article-title":"Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors","volume":"16","author":"Mason","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209332137300_R59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1005940405165","article-title":"Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination","volume":"38","author":"Slavc","year":"1998","journal-title":"J Neurooncol"},{"key":"2021122209332137300_R60","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1073\/pnas.93.13.6610","article-title":"Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI","volume":"93","author":"Young","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209332137300_R61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3171\/jns.2000.92.2.0249","article-title":"Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration","volume":"92","author":"Packer","year":"2000","journal-title":"J Neurosurg"},{"key":"2021122209332137300_R62","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"2021122209332137300_R63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0360-3016(01)02641-4","article-title":"Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity","volume":"52","author":"Huang","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.8-2-174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.8-2-174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/2\/174\/41840501\/oncolo_8_2_174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/2\/174\/41840501\/oncolo_8_2_174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:52:08Z","timestamp":1640191928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/8\/2\/174\/6387567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,1]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2003,4,1]]},"published-print":{"date-parts":[[2003,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.8-2-174","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,4,1]]},"published":{"date-parts":[[2003,4,1]]}}}